Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging
暂无分享,去创建一个
G. M. Godbersen | S. Kasper | A. Hahn | W. Wadsak | M. Mitterhauser | R. Lanzenberger | T. Vanicek | V. Pichler | M. Hacker | M. Klöbl | M. B. Reed | G. Godbersen | G. Gryglewski | P. Michenthaler | M. Hartenbach | L. Rischka | N. Berroterán-Infante | G. M. James | A. Kautzky | C. Vraka | E. Klebermass | M. Hienert | J. Unterholzner | T. Balber | L. Silberbauer | E. Winkler-Pjrek
[1] Siegfried Kasper,et al. Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI , 2018, NeuroImage.
[2] L. Reneman,et al. Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity , 2018, European Neuropsychopharmacology.
[3] Siegfried Kasper,et al. Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging , 2018, NeuroImage.
[4] J. Dukart,et al. Test-retest reliability of task-based and resting-state blood oxygen level dependence and cerebral blood flow measures , 2018, bioRxiv.
[5] Nicolas Costes,et al. In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging , 2018, Neuropsychopharmacology.
[6] Christopher H. Chatham,et al. Cerebral blood flow predicts differential neurotransmitter activity , 2017, bioRxiv.
[7] B. Rosen,et al. Functional Characterization of 5-HT1B Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR , 2017, The Journal of Neuroscience.
[8] Lucas Rischka,et al. Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion , 2017, NeuroImage.
[9] Alan C. Evans,et al. Biomarkers, designs, and interpretations of resting‐state fMRI in translational pharmacological research: A review of state‐of‐the‐Art, challenges, and opportunities for studying brain chemistry , 2017, Human brain mapping.
[10] Christian Windischberger,et al. Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control , 2017, NeuroImage.
[11] G. Kranz,et al. Ketamine-dependent neuronal activation in healthy volunteers , 2016, Brain Structure and Function.
[12] N. Costes,et al. Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study , 2016, Scientific Reports.
[13] Christian Windischberger,et al. (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling , 2015, NeuroImage.
[14] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015 , 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[15] Serge A. R. B. Rombouts,et al. Single-dose serotonergic stimulation shows widespread effects on functional brain connectivity , 2014, NeuroImage.
[16] D. Margulies,et al. Serotonergic Modulation of Intrinsic Functional Connectivity , 2014, Current Biology.
[17] Bruce R. Rosen,et al. A receptor-based model for dopamine-induced fMRI signal , 2013, NeuroImage.
[18] Aart J. Nederveen,et al. Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI , 2013, NeuroImage.
[19] David Borsook,et al. Parallel Buprenorphine phMRI Responses in Conscious Rodents and Healthy Human Subjects , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[20] Aart J. Nederveen,et al. Feasibility of ASL-based phMRI with a single dose of oral citalopram for repeated assessment of serotonin function , 2012, NeuroImage.
[21] U. Heinemann,et al. Fluoxetine induces vasodilatation of cerebral arterioles by co-modulating NO/muscarinic signalling , 2012, Journal of cellular and molecular medicine.
[22] J. Booij,et al. Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI , 2012, European Neuropsychopharmacology.
[23] Shane McKie,et al. Differential Effects of Anaesthesia on the phMRI Response to Acute Ketamine Challenge. , 2012, British journal of medicine and medical research.
[24] Francesco de Pasquale,et al. Differential response to specific 5-Ht(7) versus whole-serotonergic drugs in rat forebrains: A phMRI study , 2011, NeuroImage.
[25] R Dudczak,et al. Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[26] G. Glover,et al. Methods and Software for fMRI Analysis of Clinical Subjects , 2009, NeuroImage.
[27] Shane McKie,et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. , 2008, Archives of general psychiatry.
[28] C. Bundgaard,et al. An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. , 2007, Journal of pharmacological and toxicological methods.
[29] Angelo Bifone,et al. Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI , 2007, Journal of Neuroscience Methods.
[30] D. Townsend,et al. Method for transforming CT images for attenuation correction in PET/CT imaging. , 2006, Medical physics.
[31] F. Larsen,et al. The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects , 2005, Journal of clinical pharmacology.
[32] R. Elliott,et al. Neuronal effects of acute citalopram detected by pharmacoMRI , 2005, Psychopharmacology.
[33] Bengt Långström,et al. Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies. , 2005, Nuclear medicine and biology.
[34] Sylvain Houle,et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.
[35] Sylvain Houle,et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.
[36] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[37] Alan A. Wilson,et al. Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[38] R. Turner,et al. Characterization and Correction of Interpolation Effects in the Realignment of fMRI Time Series , 2000, NeuroImage.
[39] F. Artigas,et al. Modulation of the Extracellular 5-Hydroxytryptamine Brain Concentrations by the Serotonin and Noradrenaline Reuptake Inhibitor, Milnacipran Microdialysis Studies in Rats , 1999, Neuropsychopharmacology.
[40] Roberto Invernizzi,et al. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex , 1992, Brain Research.